VR Logo

Elevation Oncology Inc. (ELEV) download report


Healthcare | Biotechnology & Pharma Research

Elevation Oncology Inc. (ELEV) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

IPO Date: 25-Jun-2021

Founder, Pres, CEO & Director: Dr. Shawn M. Leland Pharm.D., R.Ph.

Chief Financial Officer: Mr. Joseph J. Ferra Jr.

Listing: NASDAQ: ELEV

Country: United States

Headquarters: New York, NY

Website: https://elevationoncology.com

Key Facts

Market cap: $33.49 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-44.22 Mln

Cash: $132.06 Mln

Total Debt: $0.00 Mln

Insider's Holding: 2.19%

Liquidity: Low

52 Week range: $1.20 - 16.22

Shares outstanding: 23,254,000

Stock Performance

Time Period Elevation Oncology (ELEV) S&P BSE Sensex* S&P Small-Cap 600*
YTD-76.08-8.62-18.78
1 month-52.48-4.54-8.00
3 months-42.86-10.19-13.65
1 Year-89.391.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022